Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 4/20 | 0.34 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.34 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 3/20 | 0.32 |
| ▸ | AXL | P30530 | 2/20 | 0.32 |
| ▸ | BRAF | P15056 | 1/20 | 0.32 |
| ▸ | TTK | P33981 | 4/20 | 0.32 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.31 |
| ▸ | IGF1R | P08069 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30349525 | 0.97 | SYK (0.36) | SYKMAPKAPK5PTK6IDO1AXL | |
| SCHEMBL22124567 | 0.97 | SYK (0.36) | SYKMAPKAPK5PTK6IDO1AXL | |
| SCHEMBL22124871 | 0.91 | SYK (0.39) | SYKMAPKAPK5PTK6IDO1AXL | |
| SCHEMBL22124653 | 0.91 | SYK (0.39) | SYKMAPKAPK5PTK6AXLBRAF | |
| SCHEMBL24112311 | 0.91 | PTK6 (0.35) | SYKMAPKAPK5PTK6IDO1AXL | |
| SCHEMBL22124815 | 0.90 | TTK (0.39) | SYKMAPKAPK5PTK6IDO1BRAF | |
| SCHEMBL25450746 | 0.89 | PTK6 (0.35) | SYKMAPKAPK5PTK6IDO1AXL | |
| SCHEMBL22123578 | 0.89 | SYK (0.36) | SYKMAPKAPK5PTK6IDO1AXL | |
| SCHEMBL22124604 | 0.89 | PTK6 (0.41) | SYKMAPKAPK5PTK6IGF1R | |
| SCHEMBL30385354 | 0.89 | SYK (0.36) | SYKMAPKAPK5PTK6IDO1AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230141600-A1 | IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-05-11 | — | — | US | disclosed |
| EP-4161931-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2023-04-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230141600-A1 | IMIDAZOPYRAZINE DERIVATIVES | IKZF3, RRP15, IK | SYK 256/4885MAPKAPK5 508/4885PTK6 925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.